{"page":{"totalFilteredElements":66},"studies":[{"active":true,"description":"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung","eudractNumber":"2018-003691-12","id":5573,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"},{"name":"MSI-H","id":"mt_52"},{"name":"Mismatch Repair Deficiency (dMMR)","id":"mt_270"}],"nctNumber":"NCT04089631","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-08-07T10:52:25+02:00","shortTitle":"Circulate AIO-KRK-0217","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"The DEFINITIVE Trial: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer","eudractNumber":null,"id":9925,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PgR (Progesteronrezeptor)","id":"mt_221"},{"name":"ER (Östrogenrezeptor)","id":"mt_248"},{"name":"HER2/neu","id":"mt_19"},{"name":"HER2+","id":"mt_284"}],"nctNumber":"NCT06446882","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-09-17T11:22:14+02:00","shortTitle":"DEFINITIVE","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"DESTINY-Biliary\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\nCancer","eudractNumber":"2023-508057-19-00","id":10413,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06467357","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-04-14T09:21:26+02:00","shortTitle":"DESTINY-BTC 01 D781PC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Phase 3, Randomized, Open-Label Study of Belentamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnose Multiple Myeloma who are inelegible for ASCT<br />","eudractNumber":"2024-516030-35-00","id":10407,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-06T08:42:39+02:00","shortTitle":"DREAMM-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Lenalidomide, Adriamycin, Dexamethasone \n(RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction\n in Newly Diagnosed Multiple Myeloma Followed by Response-adapted \nConsolidation and Lenalidomide Maintance &#8211; A Randomized Multicenter \nPhase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)","eudractNumber":"2009-016616-21","id":414,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT01685814","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2012-07-20T12:37:36+02:00","shortTitle":"DSMM XIV","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued</div><div>Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients</div>","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase III, Randomized, Open-Label, Multi-Center, Global&#160;Study of Volrustomig (MEDI5752) as Sequential Therapy Versus&#160;Observation in Participants with Unresected Locally Advanced&#160;Head and Neck Squamous Cell Carcinoma, Who Have Not&#160;Progressed Following Definitive Concurrent Chemoradiotherapy&#160;(eVOLVE-HNSCC)<div><br /></div><div><b>D798EC00001</b><br /></div>","eudractNumber":"2023-506294-36","id":9113,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"},{"name":"CTLA-4 (cytotoxic T-lymphocyte-associated Protein 4)","id":"mt_42"},{"name":"HPV16","id":"mt_86"}],"nctNumber":"NCT06129864","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-10-21T08:46:14+02:00","shortTitle":"EVOLVE-HNSCC D798EC00001","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"<div>A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)</div>","eudractNumber":"2024-513586-39","id":12223,"indications":[{"id":"pro","name":"Prostatakrebs"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06952803","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-03-20T09:20:13+01:00","shortTitle":"EvoPar-Prostate02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \"PREVENT\" Trial of the AIO /CAOGI /ACO<div><br /></div>","eudractNumber":"2017-003832-35","id":6238,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04447352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-12-16T13:37:56+01:00","shortTitle":"HIPEC/FLOT9 (PREVENT)","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)","eudractNumber":"2023-510292-65-00","id":11651,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06585774","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T12:53:35+01:00","shortTitle":"INCA034176-357","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}